Acquired Immune Deficiency Syndrome (AIDS)



A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a


Condition:   HIV Infections
Intervention:   Other: Blood sample
Sponsor:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting


Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine


Condition:   HIV Infections
Interventions:   Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension;   Biological: Bivalent Subtype C gp120
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network;   Sanofi Pasteur, a Sanofi Company;   GlaxoSmithKline
Recruiting


Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males


Condition:   HIV Seropositivity
Intervention:   Device: PrePex male circumcision device
Sponsors:   University of Washington;   Centers for Disease Control and Prevention;   Ministry of Health and Child Care, Zimbabwe;   University of Zimbabwe;   Zimbabwe Community Health Intervention Research Project (ZiCHIRe), Zimbabwe
Completed


Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia


Condition:   HIV Seropositivity
Intervention:   Other: Stop of ART
Sponsor:   Ospedale San Raffaele
Recruiting


Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants


Condition:   HIV Infections
Interventions:   Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   GlaxoSmithKline;   Sanofi Pasteur, a Sanofi Company
Not yet recruiting


Randomised Study Comparing Two HIV Screening Strategies


Condition:   HIV Infections
Intervention:   Diagnostic Test: Rapid HIV test
Sponsor:   University of Lausanne Hospitals
Completed


Safety and Immune Response to a Clade C DNA HIV Vaccine


Condition:   HIV Infections
Interventions:   Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network;   IPPOX Foundation;   Novartis Vaccines
Recruiting


Community-based Distribution of Oral HIV Self-testing Kits


Condition:   HIV Seropositivity
Intervention:   Device: OraQuick® HIV Self-Test (Orasure Technologies, Thailand)
Sponsors:   Zambart;   London School of Hygiene and Tropical Medicine
Not yet recruiting


Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring


Condition:   HIV Infections
Interventions:   Combination Product: Dapivirine Vaginal Ring;   Combination Product: Placebo vaginal ring
Sponsor:   International Partnership for Microbicides, Inc.
Completed


VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption


Condition:   HIV
Intervention:   Biological: VRC-HIVMAB060-00-AB (VRC01)
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine


Condition:   HIV
Intervention:   Behavioral: Modified Antiretroviral Treatment Access Study intervention
Sponsor:   Ukrainian Institute on Public Health Policy
Completed



Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection


Condition:   HIV
Intervention:  
Sponsor:   Sichuan Academy of Medical Sciences
Recruiting


Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)


Condition:   HIV
Interventions:   Behavioral: Social Network Intervention;   Behavioral: Counsel, Test, and Treat
Sponsors:   Medical College of Wisconsin;   Mississippi State University;   AIDS Task Force of Greater Cleveland
Active, not recruiting


Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants


Conditions:   HIV;   HIV Infections
Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
Sponsor:   Gilead Sciences
Active, not recruiting


Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention


Condition:   HIV Infection
Intervention:   Behavioral: Community Mobilization
Sponsor:   University of North Carolina, Chapel Hill
Completed


Vitamin D Supplementation in HIV Youth


Condition:   HIV Infections
Intervention:   Drug: Vitamin D3
Sponsors:   University Hospitals Cleveland Medical Center;   Emory University
Completed


Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.


Condition:   HIV Infection
Interventions:   Drug: 300mg TMC278LA;   Drug: 150mg TMC278LA;   Drug: 1200mg TMC278LA;   Drug: 600mg TMC278LA
Sponsor:   St Stephens Aids Trust
Completed


A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells


Conditions:   HIV Infections;   Acquired Immune Deficiency Syndrome
Interventions:   Drug: Raltegravir plus Truvada;   Drug: Atripla
Sponsors:   Community Research Initiative of New England;   Merck Sharp & Dohme Corp.
Withdrawn


Antigenic Competition in HIV Preventive Vaccines


Condition:   HIV Infections
Interventions:   Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults


Condition:   HIV Infections
Interventions:   Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


HIV Persistence and Viral Reservoirs


Conditions:   HIV;   HIV Infections
Intervention:   Drug: Raltegravir, tenofovir/emtricitabine
Sponsors:   University of California, San Francisco;   California HIV/AIDS Research Program;   Gilead Sciences;   Merck Sharp & Dohme Corp.
Unknown status


Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults


Condition:   HIV Infections
Intervention:   Biological: Ad5.ENVA.48 HIV-1 vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting


Family-based HIV Prevention for Adolescent Girls


Condition:   HIV Infections
Intervention:   Behavioral: Family-Based Risk Reduction Intervention
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed


HIV Vaccine Trial in Thai Adults


Condition:   HIV Infection
Interventions:   Biological: ALVAC-HIV vCP1521 + AIDSVAX;   Biological: ALVAC Placebo + AIDSVAX Placebo
Sponsors:   U.S. Army Medical Research and Materiel Command;   United States Army Medical Materiel Development Activity;   Armed Forces Research Institute of Medical Sciences, Thailand;   Walter Reed Army Institute of Research (WRAIR);   MCM Vaccines B.V.;   VaxGen;   The EMMES Corporation;   Ministry of Health, Thailand;   Mahidol University;   Royal Thai Army Medical Department;   Tripler Army Medical Center;   Henry M. Jackson Foundation for the Advancement of Military Medicine
Completed

Refine Your Search Advanced Search